Expectant mums ‘at increased risk of swine flu complications’June 16th, 2009 - 12:35 pm ICT by ANI
Washington, June 16 (ANI): Pregnant women, especially those in the third trimester, are at an increased risk of serious complications from the H1N1 A influenza virus, says a new report.
With the H1N1 flu outbreak now elevated to pandemic level, the article in CMAJ (Canadian Medical Association Journal) has reported that oseltamivir (Tamiflu) and zanamivir (Relenza) are relatively safe drugs for use in pregnant and breast-feeding women.
The study was conducted by researchers from the Motherisk Program at The Hospital for Sick Children (SickKids) in Toronto and the Japan Drug Information Institute in Pregnancy in Tokyo, Japan.
For treatment or prevention during the current pandemic, “oseltamivir appears to be the drug of choice because there are more data on its safety in pregnancy,” writes Dr. Shinya Ito, Head of the Division of Clinical Pharmacology and Toxicology at SickKids.
Zanamivir can be used, although there is less data available about its safety in pregnant women, the expert added.
Neither drug appears to affect the growth and development of the fetus, although ongoing data collection is important. The groups at high risk of flu-related complications from the novel H1N1 influenza are the same as those for seasonal flu - pregnant women, children under 5 years, the elderly and others such as those with chronic lung conditions.
Only small amounts of oseltamivir and zanamivir are excreted into human milk. If an infant is breastfed by the mother on these drugs and needs treatment, the recommended dose of oseltamivir or zanamivir should be given to the infant. (ANI)
Tags: breast feeding women, canadian medical association, canadian medical association journal, clinical pharmacology, cmaj, expectant mums, flu complications, flu outbreak, growth and development of the fetus, influenza virus, lung conditions, medical association journal, motherisk program, oseltamivir, relenza, shinya ito, swine flu, tokyo japan, zanamivir, zanamivir relenza